Phase III success for first new gonorrhea treatment in decades

2 November 2023

A new first-in-class antibiotic, zoliflodacin, has been shown to be effective in the treatment of gonorrhea, in a Phase III trial.

Sponsored by the Global Antibiotic Research & Development Partnership (GARDP) and a division of Innoviva (Nasdaq: INVA), the trial met its primary endpoint, showing non-inferiority compared with a current global standard of care regimen.

Innoviva Specialty Therapeutics and GARDP hope to address a World Health Organization priority pathogen and bring to market the first new antibiotic for gonorrhea in decades.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK